2016-09-20 |
327 |
|
harma”).’
The patents-in-suit are Patent Nos. 9,006,289 (“the ‘289 patent”
… —
“289 Patent” United States Patent No. 9,006,289, P1. Ex. 1 (ECF No.
…of the
4 (See, e.g., ‘289 Patent Claim 1; ‘238 Patent Claim 1; ‘239 Patent
buffer.
…’s construction of key patent terms
following a Markman hearing. This patent infringement case is brough…PageID: 7183
(“the ‘238 patent”), and 9,168,239 (“the ‘239 patent”).
|
External link to document |
2016-09-20 |
328 |
|
is for patent infringement. The patents-in-suit are Patent Nos. 9,006,289 (“the
‘289 patent”), 9,168,238…253-
4)).
“‘289 Patent” — United States Patent No. 9,006,289, P1. Ex. 1 (ECF No. 187—2)…limited patent monopoly. Where the patent holder is acting
within the lawful scope of its patent, public…9,168,238 (“the ‘238 patent”), and 9,168,239 (“the ‘239 patent”).
All three describe formulations of levothyroxine…2).
“238 Patent” — United States Patent No. 9,168,238, P1. Ex. 2 (ECF No. 187—3).
|
External link to document |
2016-09-23 |
333 |
|
is for patent infringement. The patents-in-suit are Patent Nos. 9,006,289 (“the
‘289 patent”), 9,168,238…253-
4)).
“289 Patent” — United States Patent No. 9,006,289, P1. Ex. 1 (ECF No. 187—2)…limited patent monopoly. Where the patent holder is acting
within the lawful scope of its patent, public…9,168,238 (“the ‘238 patent”), and 9,168,239 (“the ‘239 patent”).
All three describe formulations of levothyroxine…2).
“238 Patent” — United States Patent No. 9,168,238, P1. Ex. 2 (ECF No. 187—3).
|
External link to document |